Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from its lead development candidate, PRT13722. The company price a $90 million offering of 18 million shares at $4.44 per share.

PRLD

<p>Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from its lead development candidate, PRT13722. The company price a $90 million offering of 18 million shares at $4.44 per share.</p>

benzinga_article

Prelude Therapeutics

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

VG Health

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

News